Japan is the only country where alpha-fetoprotein (AFP)-L3 can be measured in the routine clinical setting. Since AFP-L3 examination has been covered by health insurance in Japan for over 10 years, it is now routinely measured during general medical checkups for patients with chronic liver disease. To increase the specificity of AFP, the AFP-L3 glycoform can be used as a measure of cancerous changes in the AFP composite carbohydrate moiety. The most frequently used cut-off value is 10% [1], which gives a positive rate of 0/71 (0.0%), 1/90 (1.1%), 0/13 (0.0%), 0/14 (0.0%), and 18/82 (22.0%) for chronic hepatitis, hepatic cirrhosis, dysplastic nodules, early hepatocellular carcinoma, and advanced hepatocellular carcinoma, respectively. This yields a sensitivity of 18.8% and a specificity of 99.4%. Therefore, although AFP-L3 has high specificity, due to its low sensitivity, it is considered to be of limited use in screening. It is possible, however, to diagnose a marginally higher number of patients with advanced hepatocellular carcinoma [2] . Furthermore, as AFP-L3 may be elevated during hepatic failure, interpretation should be made with caution.
high degree of biological malignancy, when negative conversion is induced from therapeutic intervention, a survival rate equivalent to that of AFP-L3-negative cancer can be obtained.
Recently, highly sensitive AFP-L3 measurements have become available, and the usefulness of these has increased rapidly [5, 6] . Using conventional methods, AFP-L3 measurement was only possible at AFP levels >10 ng/ml, whereas using the highly sensitive method enables measurement at AFP levels >2 ng/ml. The highly sensitive AFP-L3 measurements are particularly effective in patients with low AFP values. In an investigation of 270 hepatocellular carcinoma patients with an AFP value >20 ng/ml and a Child-Pugh score of A or B [5] , when the cut-off value was set at 5%, the conventional AFP-L3 measurement method yielded a sensitivity of 7% and a specificity of 98.5%. Conversely, the highly sensitive method yielded a sensitivity of 41.5% and a specificity of 85.1%, indicating that the sensitivity of the highly sensitive method was significantly higher than that of the conventional method (p < 0.05).
Furthermore, the sensitivity for Stage I (n = 89) and Stage II (n = 127) was 4.5% and 2.4%, respectively when the cut-off value using the conventional method was set at 10%, while the sensitivity for the same stages was more favorable at 34.8% and 42.5%, respectively when the cut-off value using the highly sensitive method was set at 5%. In terms of prognostic assessment, when using the conventional method with the cut-off value set at 10%, no significant difference was observed between those with values >10% or <10%. However, reports indicate that when using the highly sensitive method with a cut-off value of 5%, patients with values < 5% have a significantly more favorable prognosis than those with values >5% (p < 0.01). In addition, even in patients with an AFP <10 ng/ml, when the cut-off value is set at 5% using the highly sensitive method, patients with values below 5% have a significantly more favorable prognosis than those with values 5% or above (p = 0.035). With regard to prognosis and the use of AFP-L3, multivariate analysis using the Cox proportional hazard model showed the following. For values of 5% and above the hazard ratio was 1.697 and 95% confidence interval was 1.066 − 3.440, p = 0.026. For treatment consisting of nonhepatic resection the hazard ratio was 3.627 and 95% confidence interval was 2.066 − 6.708, p < 0.001. These findings enabled factors contributing to prognosis to be selected [5] .
In conclusion, AFP-L3, in particular its high sensitivity measurement, is extremely useful as an index of prognostication and for the degree of biological malignancy of hepatocellular carcinoma. Consequently, it is highly expected that AFP-L3 will become more popular worldwide, and not just in Japan.
